GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (LTS:0WA2) » Definitions » Shiller PE Ratio

Cellectis (LTS:0WA2) Shiller PE Ratio : (As of May. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cellectis Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectis Shiller PE Ratio Historical Data

The historical data trend for Cellectis's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Shiller PE Ratio Chart

Cellectis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cellectis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cellectis's Shiller PE Ratio

For the Biotechnology subindustry, Cellectis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's Shiller PE Ratio falls into.



Cellectis Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cellectis's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Cellectis's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.642/118.3900*118.3900
=-0.642

Current CPI (Dec. 2023) = 118.3900.

Cellectis Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201306 -0.848 99.700 -1.007
201312 0.000 99.800 0.000
201406 0.000 100.180 0.000
201412 0.000 99.860 0.000
201503 0.190 100.170 0.225
201506 -0.630 100.440 -0.743
201509 -0.361 99.950 -0.428
201512 0.231 100.040 0.273
201603 -0.855 100.020 -1.012
201606 -0.178 100.630 -0.209
201609 -0.356 100.340 -0.420
201612 -0.349 100.650 -0.411
201703 -0.524 101.170 -0.613
201706 -0.668 101.320 -0.781
201709 -0.612 101.330 -0.715
201712 -0.642 101.850 -0.746
201803 -0.576 102.750 -0.664
201806 -0.146 103.370 -0.167
201809 -0.463 103.560 -0.529
201812 -0.466 103.470 -0.533
201903 -0.319 103.890 -0.364
201906 -0.699 104.580 -0.791
201909 -0.345 104.500 -0.391
201912 -0.792 104.980 -0.893
202003 0.425 104.590 0.481
202006 -0.675 104.790 -0.763
202009 -0.603 104.550 -0.683
202012 -0.781 104.960 -0.881
202103 -0.235 105.750 -0.263
202106 -0.730 106.340 -0.813
202109 -0.697 106.810 -0.773
202112 -0.841 107.850 -0.923
202203 -0.636 110.490 -0.681
202206 -0.397 112.550 -0.418
202209 -0.636 112.740 -0.668
202212 -0.557 114.160 -0.578
202303 -0.542 116.790 -0.549
202306 -0.175 117.650 -0.176
202309 -0.290 118.260 -0.290
202312 -0.642 118.390 -0.642

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cellectis  (LTS:0WA2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cellectis Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cellectis's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (LTS:0WA2) Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (LTS:0WA2) Headlines

No Headlines